Is Eli Lilly Alzheimer's medication about to be approved? Supported by FDA advisory panel, with a market value exceeding $800 billion for the first time
海角七号
发表于 2024-6-11 16:18:56
206
0
0
The Alzheimer's drug donanemab from pharmaceutical giant Eli Lilly is about to receive a green light from US regulatory agencies.
The advisory committee of 11 independent experts convened by the US Food and Drug Administration (FDA) unanimously voted that donanemab is an "effective" drug for treating Alzheimer's disease, and the benefits of this experimental treatment outweigh the risks.
Stronger therapeutic effect
Lilly's donamab is a new treatment method that slows down cognitive decline in early Alzheimer's disease patients by removing amyloid plaques associated with the disease.
For a long time, analysts have predicted that donanemab will surpass the only existing Alzheimer's disease treatment drug, Leqembi, because donanemab has higher efficacy in clinical trials and only needs to be administered once a month instead of every two weeks.
In the Phase III trial, compared to the placebo group, Leqembi slowed down cognitive decline by 27%, while Donanemab slowed down cognitive decline by 35%.
However, donanemab and similar drugs have safety issues related to brain swelling and cerebral hemorrhage, and three patients died due to brain swelling events.
In March of this year, the FDA requested a review of the drug and delayed its approval due to concerns about its safety as it may cause brain swelling. The FDA has decided to convene an external expert meeting to discuss the safety and efficacy of its drugs.
More data needed
Although the FDA's external advisory committee has recognized donanemab, the FDA still points out that more data is needed to understand the impact of the drug on patients with low or no Tau protein levels, as Lilly has excluded these patients from clinical trials.
Tau protein is a protein associated with Alzheimer's disease, and its level is one of the core indicators for diagnosing Alzheimer's disease.
Committee member and Cornell University professor Costantino Iadecola said, "If some subgroups require further analysis, then this drug should not be hindered from being made available to the public."
Nilufer Ertekin Taner, a neurogeneticist at the Mayo Foundation, stated that more data is needed for certain groups, such as those with Down syndrome.
The recommendations of this committee are not binding, but the FDA typically follows the recommendations of such committees.
Boosting stock prices
The support of this advisory committee is a boost for this pharmaceutical giant.
As of Monday's close, the company's stock price closed up 1.8%. On that day, the stock price reached a historic high, with a market value exceeding 800 billion US dollars.
Mark Mintun, Vice President of Neuroscience Research and Development at Lilly, stated that the company is "pleased that the committee unanimously recognizes Donanemab's pros and cons comparison.".
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Nvidia sets first new closing high in four months: Will it once again impact the world's No.1 market value?
- TSMC's market value exceeds $1 trillion, becoming the first Chinese concept stock to achieve this milestone
- Top 20 US stock market transactions: Nvidia hits historic high, market value exceeds $3.5 trillion
- Tesla exploded! The stock price has risen by nearly 22%, and the market value has increased by $150 billion! What happened?
- 200 billion dollar pharmaceutical company officially responds to executive investigation
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- What is the cost of missing out on the AI craze? Samsung Electronics plummeted 32%, evaporating $122 billion in market value
- Bezos plans to sell $3.05 billion worth of Amazon stock
- Top 20 US stock transactions: Trump Media Technology Group's stock price surged by 12%; Nvidia once became the world's most valuable company during trading
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏